Gene therapy for wet age-related macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 50 and 80 years
- Diagnosis of wet AMD in one eye (the study eye)
- Previous treatment with aflibercept (e.g., Eylea) that showed some improvement in vision
- No anti-VEGF injections (like Eylea or Avastin) in the study eye for at least 28 days before screening
- Must have had cataract surgery in the study eye (the natural lens is replaced with an artificial one)
- No history of certain eye conditions like retinal detachment, uveitis, or advanced glaucoma, and no prior vitrectomy (eye surgery removing the gel inside the eye)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests a new CRISPR-based gene therapy injected into the eye to treat wet age-related macular degeneration (AMD). It aims to stop the growth of abnormal blood vessels that damage your vision.
This trial tests a new CRISPR-based treatment for wet age-related macular degeneration (AMD). It aims to stop vision loss by targeting the cause of abnormal blood vessel growth in the eye. This study is for people who have already tried anti-VEGF injections but might not be responding well enough.
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
This trial tests a new gene therapy (LX111) for people with wet age-related macular degeneration (AMD) who have already been helped by standard anti-VEGF injections. The goal is to see if one dose of LX111 can reduce the need for frequent eye injections.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.